Elevance Health (ELV) Fell Due to Reduced Guidance

Core Insights - Impax Asset Management's "Impax US Sustainable Economy Fund" underperformed the Russell 1000 in Q3 2025, returning 7.33% compared to the index's 7.99% [1] - The fund's strategy focused on lower-risk and high-quality factors, which contributed to its underperformance in a risk-on market environment [1] Company Performance - Elevance Health, Inc. (NYSE:ELV) reported a one-month return of 1.80% and a 52-week decline of 4.32%, with a closing stock price of $366.69 and a market capitalization of $82.571 billion as of January 7, 2026 [2] - Elevance Health's operating revenue for Q3 2025 was $50.1 billion, reflecting a year-over-year increase of 12% [4] Earnings Guidance - Elevance Health's stock experienced a decline due to the company lowering its full-year earnings estimates by over 10% due to increased costs in Medicaid and Affordable Care Act plan channels [3]